Come up with a name for your new list and we'll add to it:
IFM Therapeutics was acquired by
Bristol-Myers Squibb on August 03, 2017.
IFM Therapeutics is a biopharmaceutical company developing a portfolio of first-in-class small molecules targeting the innate immune system. IFM Therapeutics is developing modulators of novel targets …